Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
56
days
Real-world treatment patterns and survival in advanced/metastatic triple-negative breast cancer in Japan
AuthorsHitomi Sanno; Yuichiro Ito; Kazuko Taniguchi; Yuya Yoshimoto; Shigehira Saji
Affiliations1. MSD K.K; 2. Fukushima Medical University
95
days
LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO)
AuthorsSarah Sharman Moser; Alona Zer; Andre Hejazi; Netta Passwell; Moshe Hoshen; Amin Virani; Simon Sharmokh; Nathalie Daaboul; Sivan Gazit; Jair Bar
Affiliations1. Maccabi Healthcare Services; 2. Rambam Health Care Campus, Technion Israel Technology Institutes; 3. AbbVie Inc; 4. Université de Sherbrooke Canada; 5. Sheba Medical Center; 6. Tel Aviv University
85
days
Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region
AuthorsAnas Hamad; Ahmed El-Sheashaey; Ahmed S. Alanazi; Fahmeeda Khan; Mansoor Ahmed Khan; Mohammed Alfar; Osama Abu Tabar; Rana Aljaber; Shereen Elazzazy
Affiliations1. Hamad Medical Corporation; 2. Qatar University; 3. Kuwait Cancer Control Center (KCCC); 4. King Fahad Medical City; 5. RMS Hospitals; 6. King Abdulaziz Medical City; 7. Burjeel Cancer Institute; 8. Cleveland Clinic Abu Dhabi; 9. Case Western Reserve University; 10. University Medical City (UMC); 11. National University of Science and Technology
141
days
Complications following small-molecule inhibitors for non-small cell lung cancer
AuthorsCaroline Kamali; Simon Ekman
Affiliations1. Karolinska Institutet; 2. Karolinska University Hospital
84
days
Artificial intelligence in retinoblastoma and uveal melanoma - a narrative review
AuthorsBharat Gurnani; Kirandeep Kaur
Affiliations1. Gomabai Netralaya
272
days
Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study
AuthorsAbay Jumanov; Dilyara Kaidarova; Alma Zhylkaidarova; Innara Turkpenova; Ainash Oshibayeva; Yernar Myrzakulov
Affiliations1. Kazakh Institute of Oncology and Radiology; 2. Khoja Akhmet Yassawi International Kazakh-Turkish University; 3. Tengri LLP
59
days
177 Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer
AuthorsCarolina Sciortino; Amedeo Nuzzo; Marco Stellato; Melanie Claps; Alessandro Rametta; Valentina Guadalupi; Eleonora Gusmaroli; Simone Rota; Federica Mascaro; Patrizia Giannatempo; Matteo Zimatore; Marco Maccauro; Veronica Huber; Elena Verzoni; Giuseppe Procopio
Affiliations1. Fondazione IRCCS Istituto Nazionale dei Tumori di Milano; 2. Fondazione IRCCS Istituto Nazionale Tumori; 3. Fondazione IRCCS Istituto Nazionale dei Tumori
109
days
From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China
AuthorsShaohong Luo; Xiangzhen Wang; Lijing Yang; Shen Lin; Xiaoting Huang; Xiuhua Weng; Xiongwei Xu
Affiliations1. Fujian Medical University; 2. Mengchao Hepatobiliary Hospital of Fujian Medical University
116
days
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer
AuthorsIoannis P. Trontzas; Anastasia Palaiologou; Natalia Kamperi; Anastasia Georganta; Emmanouil Panagiotou; Ioanna-Maria Orfanou; Konstantinos G. Kyriakoulis; Ioannis Vathiotis; Elias A. Kotteas; Dimitra Grapsa; Constantin Tamvakopoulos; Konstantinos N. Syrigos
Affiliations1. National and Kapodistrian University of Athens; 2. Biomedical Research Foundation, Academy of Athens
90
days
An evaluation of avutometinib in combination with defactinib for KRAS -mutated recurrent low-grade serous ovarian cancer
AuthorsVivek Podder; Brian M. Slomovitz; Robert L. Coleman
Affiliations1. Mount Sinai Medical Center; 2. US Oncology Network
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days